Insight Pharma Reports Releases New Business Intelligence: Drug Delivery Technologies

Feb. 9, 2011 - PRLog -- Exciting developments are occurring in the field of alternative drug delivery—a phrase that describes the reformulation of drugs to enable lower doses, more convenient delivery routes, and supplemental therapeutic indications. The Drug Delivery Technologies: Drug Reformulations and Administration Routes report presents an overview of these developments, describes the options that new formulation technologies are creating, and explores the medical and commercial perspectives.

Order and request sample pages at: http://www.insightpharmareports.com/reports_report.aspx?id=104439&r=8242

Table of Contents

CHAPTER 1
Classical Routes of Drug Delivery: Their Limitationsand the Alternatives
1.1. The Oral Route: Obvious But Limited in Non-Obvious Ways
1.2. The Parenteral Routes
1.3. Systemic Topical Delivery
1.4. What Is “Alternative” Drug Delivery?  

CHAPTER 2
The Marriage of Drugs and Devices: ReinvigoratingOld Technologies
2.1. Drug-Eluting Stents
2.2. Metered-Dose Inhalers
2.3. Programmable and Self-Programming Devices  Pumps and “Clever Pills”
2.4. Externally Triggered Release from Liposomes
2.5. Long-Acting Depots with Biodegradable Polymers
2.6. Advances in Injection Technology Needleless Injectors
Autoinjectors: From Battlefield to Living Room
2.7. New Approaches to Transdermal and Transmucosal Delivery Medicated Clothing

CHAPTER 3
Nanoscale Drug Vehicles: RedefiningDrug Delivery Technology
3.1. Two Types of Nanomedicine
3.2. Specific Characteristics of Nanoparticulates  Interaction with Biological Fluids
3.3. Improving Resorption and Organ System Barrier Penetration
3.4. Colloids: The Natural State of Nanoscale Systems in Biology
3.5. Dendrimers: Uniquely Designed Multifunctional Nanoglobules
3.6. Quantum Dots: A Very Special Type of Nanoparticle
3.7. Spherical Cages and Hollow Fibers  
3.8. Potential Medical Safety Issues with Nanostructures

CHAPTER 4
Advanced Organ and Tissue Targeting
4.1. Controlled Barrier-Penetration Technologies
4.2. Engaging Blood-Brain Barrier Transporters
4.3. Solid Tumors  Implant-Based Approaches Are Of Limited Utility
A Universe of Advanced Tumor Delivery Formulations
The Resurgence of Gold in Cancer Therapy
4.4. Intraocular Implants and Related Delivery Systems
4.5. Localized Drug Delivery in Oral Health
4.7. Protection and Healing of Blood Vessels
4.8. Summary 37

CHAPTER 5
The Challenge of Peptides and Proteins
5.1. Oral Bioavailability of Proteins: The “Holy Grail” Attained (To a Degree)
5.2. The Interplay Between Immunogenicity and Formulation
5.3. Attempts and Solutions for Insulins  Inhaled Insulin
Oral Insulin
5.4. Needle-Free Vaccination  Oral Vaccines
Transdermal and Transmucosal Vaccines
Influenza, HIV, and Hepatitis C
5.5. Pernasal and Oral Calcitonin  

CHAPTER 6
Technologies for Nucleic Acid Delivery
6.1. A New Paradigm Requires New Modalities of Delivery
6.2. Restorative Gene Therapies
6.3. RNA Interference Therapeutics

CHAPTER 7
Transdermal and Transmucosal Presentations:Selected Trends
7.1. Recent Innovations in Transdermal Delivery Systems Case Study: Transdermal Presentations for Alzheimer Drugs
7.2. Vaginal Drug Delivery: An Emerging Field  

CHAPTER 8
Advanced Drug Delivery and the Product Lifecycle
8.1. Alternative Drug Delivery: Salvaging and Extending Market Share Case Study #1: Aripiprazole, an Antipsychotic in Many Forms
Case Study #2: Staccato Loxapine, An Antipsychotic Made Inhalable
Case Study #3: Halozyme, a Subcutaneous Delivery Technology for Biotech Drugs
Case Study #4: Elan Drug Technologies, a Universal FormulationTool Provider
8.2. Patenting Alternative Delivery Methods: Walking a Narrow Line
8.3. Regulatory Challenges and Opportunities The US Process
The European Process
No “Smooth Sailing” Guaranteed For Reformulated Drugs

CHAPTER 9
Company and Pipeline Profiles
9.1. Companies with Various Focus Areas Access Pharmaceuticals
Capsulution Pharma  
Catalent Pharma Solutions
Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals Corp.
Chimerix
Selecta Biosciences
NanoViricides
Starpharma Holdings
CyDex Pharmaceuticals
Emisphere Technologies
Merrion Pharmaceuticals, Ltd.
Merrion Pharmaceuticals, LLC
Nektar Therapeutics
PolyTherics  
Oramed
Innocoll Technologies
SurModics
Calando Pharmaceuticals
9.2. Companies with a Focus on Inhalation  MannKind  
MAP Pharmaceuticals
Akela Pharma  
MicroDose Therapeutx
OptiNose US Inc.
9.3. Companies with a Focus on Transdermal Delivery  Altea Therapeutics  
Dharma Therapeutics
Intercell  
Zogenix  
NanoBio  
Vyteris
Makefield Therapeutics

CHAPTER 10
Summary and Perspectives
10.1. The Breathtaking Development of Drug Delivery
10.2. New Formulations: Twice as Lucrative as New Drugs
10.3. Lifecycle Management Rules the Strategy
10.4. The “Preprogrammed” Rise of Alternative Drug Delivery
10.5. International Cooperation Is Called For 100
10.6. The Role of Intellectual Property in Alternative Drug Delivery
10.7. Summary  

References  

Order and request sample pages at: http://www.insightpharmareports.com/reports_report.aspx?i...

# # #

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.